207 research outputs found

    Fabrication and Characterization of Vertically Aligned Graphene Gaps at THz Regime

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ) -- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์ž์—ฐ๊ณผํ•™๋Œ€ํ•™ ๋ฌผ๋ฆฌยท์ฒœ๋ฌธํ•™๋ถ€(๋ฌผ๋ฆฌํ•™์ „๊ณต), 2020. 8. ํ™์„ฑ์ฒ .In this work a vertically aligned graphene gap array composed of a c opper graphene copper structure was investigated for optical measurements at terahertz regime. The graphene gap array was manufactured by directly synthesizing graphene on the first patterned copper thin film followed by depositing the second copper layer. Structural features of the graphene between the copper thin films were characterized by Cs corrected transmission electron microscope and resonant Raman spectroscopy. The results revealed that the number of layers and the crystallinity of graphene on the copper surface can be controlled by adjusting the synthesis temperature and pre-annealing time in plasma enhanced chemical vapor deposition process. And the gap size can be defined by a multiple of van der Waals distance according to the number of graphene layers. Furthermore, the optical properties of a graphene gap slit array at terahertz regime was investigated by terahertz-time domain spectroscopy. Even though the gap size is a sub-nanometer for single layer graphene gap, the terahertz transmitted amplitude revealed that the fabricated graphene gap slit array is fully functional. The constant normalized terahertz amplitude through the graphene gap slit array in the frequency domain was explained by the graphene treated as treated as a gap materiala gap material with with a complex dielectric constant using analysis of the capacitor model. The results in this work can open a new route for the fabrication techniques and characterization of structural and optical properties in many optical, electronic and optoelectronic applications using two dimensional materials such as hexagonal boron nitride (h BN), molybdenum disulfide (MoS 2 ), and etc.๋ณธ ์—ฐ๊ตฌ๋Š” ๊ตฌ๋ฆฌ-๊ทธ๋ž˜ํ•€-๊ตฌ๋ฆฌ ๊ตฌ์กฐ๋กœ ์ˆ˜์ง์œผ๋กœ ์ •๋ ฌ๋œ ๊ทธ๋ž˜ํ•€ ๊ฐญ ์˜ ํ…Œ๋ผํ—ค๋ฅด์ธ  ํŒŒ ์˜์—ญ ์—์„œ ๊ด‘ํ•™ ์  ํŠน์„ฑ ์„ ์•Œ์•„๋ณด๊ธฐ ์œ„ํ•ด ์ง„ํ–‰ ๋˜์—ˆ๋‹ค. ๊ทธ๋ž˜ํ•€ ๊ฐญ์„ ๊ฐ–๋Š” ์Šฌ๋ฆฟ ๋ฐฐ์—ด์€ ํŒจํ„ด ๋œ ๊ตฌ๋ฆฌ ๋ฐ•๋ง‰ ์ƒ์— ๊ทธ๋ž˜ํ•€์„ ์ง์ ‘ ํ•ฉ์„ฑํ•œ ํ›„ ๊ทธ ์œ„์— ๋‘ ๋ฒˆ์งธ ๊ตฌ๋ฆฌ์ธต์„ ์ฆ์ฐฉํ•จ์œผ๋กœ์จ ์ œ์กฐ๋˜์—ˆ๋‹ค . ๊ตฌ๋ฆฌ ํ‘œ๋ฉด์—์„œ ํ•ฉ์„ฑ๋œ ๊ทธ๋ž˜ํ•€์˜ ๊ตฌ์กฐ์  ํŠน์ง•์€ ๊ตฌ๋ฉด ์ˆ˜์ฐจ ๋ณด์ • ํˆฌ๊ณผ ์ „์ž ํ˜„๋ฏธ๊ฒฝ ๋ฐ ๊ณต๋ช… ๋ผ๋งŒ ๋ถ„๊ด‘ํ•™์— ์˜ํ•ด ํŠน์„ฑํ™”๋˜์—ˆ๋‹ค. ๊ฒฐ๊ณผ๋Š” ํ”Œ๋ผ์ฆˆ๋งˆ ๊ฐ•ํ™” ํ™”ํ•™ ๊ธฐ์ƒ ์ฆ์ฐฉ ๊ณต์ •์—์„œ ํ•ฉ์„ฑ ์˜จ๋„ ๋ฐ ์‚ฌ์ „ ์—ด์ฒ˜๋ฆฌ ์‹œ๊ฐ„์„ ์กฐ์ •ํ•จ์œผ๋กœ์จ ๊ตฌ๋ฆฌ ํ‘œ๋ฉด ์ƒ์˜ ๊ทธ๋ž˜ํ•€์˜ ์ธต ์ˆ˜ ๋ฐ ๊ฒฐ์ •๋„๋ฅผ ์ œ์–ดํ•  ์ˆ˜ ์žˆ์Œ์„ ๋ฐํ˜€๋ƒˆ๋‹ค. ๋˜ํ•œ, ๊ทธ๋ž˜ํ•€ ๊ฐญ์˜ ํฌ๊ธฐ๋Š” ๊ทธ๋ฆฌํŒฌ ์ธต์˜ ์ˆ˜์— ๋”ฐ๋ฅธ ๋ฐ˜ ๋ฐ๋ฅด ๋ฐœ์Šค ๊ฑฐ๋ฆฌ์˜ ๋ฐฐ์ˆ˜์— ์˜ํ•ด ์ •ํ•ด์งˆ ์ˆ˜ ์žˆ์Œ์„ ํ™•์ธํ•˜์˜€๋‹ค. ํ…Œ๋ผํ—ค๋ฅด์ธ  ํŒŒ ์˜์—ญ ์—์„œ ๊ทธ๋ž˜ํ•€ ๊ฐญ ์Šฌ๋ฆฟ ๋ฐฐ์—ด์˜ ๊ด‘ํ•™์  ํŠน์„ฑ์„ ์กฐ์‚ฌํ•˜๊ธฐ ์œ„ํ•ด ํ…Œ๋ผํ—ค๋ฅด์ธ -์‹œ๊ฐ„์˜์—ญ ๋ถ„๊ด‘ํ•™์„ ์ˆ˜ํ–‰ํ•˜์˜€๋‹ค. ๊ฐญ ํฌ๊ธฐ๊ฐ€ ๋‹จ์ธต ๊ทธ๋ž˜ํ•€๊ฐญ์— ๋Œ€ํ•ด ์„œ๋ธŒ ๋‚˜๋…ธ๋ฏธํ„ฐ์ž„์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ  ํ…Œ๋ผํ—ค๋ฅด์ธ ํŒŒ ํˆฌ๊ณผ ์ง„ํญ์€ ์ œ์กฐ๋œ ๊ทธ๋ž˜ํ•€ ๊ฐญ ์Šฌ๋ฆฟ ๋ฐฐ์—ด์ด ํ…Œ๋ผํ—ค๋ฅด์ธ ํŒŒ ์˜์—ญ์—์„œ ์™„์ „ํžˆ ์ž‘๋™ํ•˜๋Š” ๊ฒƒ์„ ๋ณด์—ฌ์ฃผ์—ˆ๋‹ค. ํ…Œ๋ผํ—ค๋ฅด์ธ ํŒŒ์˜ ์ผ์ •ํ•œ ํˆฌ๊ณผ ์ง„ํญ์€ ์ถ•์ „๊ธฐ ๋ชจ๋ธ์„ ์ด์šฉํ•˜์—ฌ ๊ฐญ ์•ˆ์— ๊ทธ๋ž˜ํ•€์„ ๋ณต์†Œ ์œ ์ „ ์ƒ์ˆ˜๋ฅผ ๊ฐ–๋Š” ๊ฐญ ๋ฌผ์งˆ๋กœ ํ•˜์—ฌ ๋ถ„์„๋˜์—ˆ๋‹ค. ์ด ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋Š” ์œก๋ฐฉ ์ •๊ณ„ ์งˆํ™” ๋ถ•์†Œ (h(h--BN), BN), ์ดํ™ฉํ™” ๋ชฐ๋ฆฌ๋ธŒ๋ด (MoS(MoS22) ) ๋“ฑ๊ณผ ๊ฐ™์€ 2 ์ฐจ์› ๋ฌผ์งˆ์„ ์‚ฌ์šฉํ•˜์—ฌ ๊ด‘ํ•™, ์ „์ž ๋ฐ ๊ด‘์ „์ž ์‘์šฉ ๋ถ„์•ผ์—์„œ ๊ตฌ์กฐ ์ œ์ž‘ ๊ธฐ์ˆ  ๋ฐ ๊ตฌ์กฐ์ , ๊ด‘ํ•™์  ํŠน์„ฑํ™”๋ฅผ ์œ„ํ•œ ์ƒˆ๋กœ์šด ๋ฐฉ๋ฒ•์„ ์ œ์‹œํ•  ๊ฒƒ์œผ๋กœ ๊ธฐ๋Œ€๋œ๋‹ค.Chapter 1. Introduction 1 1.1 Extraordinary optical transmission 1 1.2 Field enhancement in a nanogap at THz regime 3 1.3 Sub nanometer gap using graphene 5 Chapter 2. Preparation of graphene gap array 7 2.1 Atomic layer lithography for nanogap fabrication 7 2.2 Graphene synthesis by plasma enhanced CVD 11 2.3 Fabrication of a graphene gap array 19 Chapter 3. Structural characterization of graphene gap 28 3.1 Raman measurement of the graphene 28 3.2 Defining the size of the graphene gap 42 Chapter 4. Optical properties of graphene gap array at THz regime 46 4.1 THz-time domain spectrosocpy 46 4.2 Kirchhoff integral and field enhancement 49 4.3 THz transmission for the graphene gap slit array 52 4.4 Complex dielectric constant of graphene in out-of-plane direction at THz regime 57 Chapter 5. Conclusion 63 Bibliography 65 Abstract in Korean 73Docto

    ์ค‘ํ•˜๋ถ€ ์ง์žฅ์•” ํ™˜์ž์—์„œ ์˜๊ตฌ์žฅ๋ฃจํ˜•์„ฑ์˜ ์˜ˆ์ธก์ธ์ž ํ‰๊ฐ€ : ์ˆ˜์ˆ ์ „ ํ•ญ๋ฌธ๊ธฐ๋Šฅ์— ๋Œ€ํ•œ ๋‹ค๊ธฐ๊ด€ ์ฝ”ํ˜ธํŠธ์—ฐ๊ตฌ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ) -- ์„œ์šธ๋Œ€ํ•™๊ต๋Œ€ํ•™์› : ์˜๊ณผ๋Œ€ํ•™ ์˜ํ•™๊ณผ, 2023. 2. ๊ฐ•์„ฑ๋ฒ”.Aim: Preoperative factors predictive of permanent stoma creation were investigated in a long-term follow-up of patients with mid or low rectal cancer. Methods: We included patients who underwent radical resection for mid or low rectal cancer with available data for preoperative anal function measured by manometry and Faecal Incontinence Severity Index questionnaire between January 2005 and December 2015 in three tertiary referral hospitals. A permanent stoma was defined as a stoma present until the patients last follow-up visit or death. Preoperative factors that predicted permanent stoma creation were analysed. Results: Over a median follow-up of 57.4 months (range 12โ€“143 months), a permanent stoma was created in 144/577 (25.0%) patients, including 89 (15.4%) who underwent abdominoperineal resection, one (0.2%) who underwent Hartmanns operation without reversal, 15 (2.6%) with a diverting ileostomy at the time of initial sphincter-preserving surgery without undergoing stoma reversal, and 39 (6.8%) who underwent permanent ileostomy formation after sphincter-preserving surgery. Patients with permanent stoma creation had a shorter tumour distance from the anal verge (P < 0.001), larger tumour size (P = 0.020) and higher preoperative Faecal Incontinence Severity Index score (P = 0.020). On multivariable analysis, tumour distance from the anal verge predicted permanent stoma formation (relative risk 0.53 per centimetre increase; 95% confidence interval 0.46โ€“0.60; P < 0.001) but preoperative anal function did not. Conclusion: Tumour distance from the anal verge was the only preoperative determinant of permanent stoma creation in rectal cancer patients. These data may help mid and low rectal cancer patients understand the need for permanent stoma.๋ชฉ์ : ์ค‘ํ•˜๋ถ€ ์ง์žฅ์•” ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ์žฅ๊ธฐ๊ฐ„ ์ถ”์ ๊ด€์ฐฐํ•˜์—ฌ ์˜๊ตฌ์ ์ธ ์žฅ๋ฃจ ์ƒ์„ฑ์„ ์˜ˆ์ธกํ•  ์ˆ˜ ์žˆ๋Š” ์ˆ˜์ˆ  ์ „ ์š”์ธ์„ ์•Œ์•„๋ณด๊ณ ์ž ํ•˜์˜€๋‹ค. ๋ฐฉ๋ฒ•: 2005๋…„ 1์›”๋ถ€ํ„ฐ 2015๋…„ 12์›”๊นŒ์ง€ 3๊ฐœ 3์ฐจ ๋ณ‘์›์—์„œ, ์ˆ˜์ˆ ์ „ ํ•ญ๋ฌธ์••๋ ฅ๊ฒ€์‚ฌ์™€ ๋ณ€์‹ค๊ธˆ ์ค‘์ฆ๋„ ์ง€์ˆ˜ ์„ค๋ฌธ์ง€๋ฅผ ํ†ตํ•ด ํ•ญ๋ฌธ ๊ธฐ๋Šฅ์— ๋Œ€ํ•œ ๋ฐ์ดํ„ฐ๊ฐ€ ์žˆ๋Š” ์ค‘ํ•˜๋ถ€ ์ง์žฅ์•” ํ™˜์ž ์ค‘ ๊ทผ์น˜์  ์ ˆ์ œ์ˆ ์„ ์‹œํ–‰ํ•œ ํ™˜์ž๋ฅผ ํฌํ•จํ–ˆ๋‹ค. ์˜๊ตฌ ์žฅ๋ฃจ๋Š” ํ™˜์ž๊ฐ€ ๋งˆ์ง€๋ง‰์œผ๋กœ ๋ฐฉ๋ฌธํ•˜๊ฑฐ๋‚˜ ์‚ฌ๋งํ•  ๋•Œ๊นŒ์ง€ ์กด์žฌํ•˜๋Š” ์žฅ๋ฃจ๋กœ ์ •์˜๋˜์—ˆ๋‹ค. ์˜๊ตฌ์ ์ธ ์žฅ๋ฃจ ์ƒ์„ฑ์„ ์˜ˆ์ธกํ•˜๋Š” ์ธ์ž๋ฅผ ์ˆ˜์ˆ  ์ „ ์š”์ธ์„ ์ด์šฉํ•˜์—ฌ ๋ถ„์„ํ•˜์˜€๋‹ค. ๊ฒฐ๊ณผ: ์ค‘์•™๊ฐ’ 57.4๊ฐœ์›”(12-143๊ฐœ์›”)์˜ ์ถ”์  ๊ธฐ๊ฐ„ ๋™์•ˆ 144/577(25.0%)์˜ ํ™˜์ž์—์„œ ์˜๊ตฌ ์žฅ๋ฃจ๊ฐ€ ์ƒ์„ฑ๋˜์—ˆ์œผ๋ฉฐ, ์ด๋Š” ์ฒซ ์ˆ˜์ˆ ์—์„œ ๋ณตํšŒ์Œ์ ˆ์ œ์ˆ ์„ ๋ฐ›์€ 89๋ช…(15.4%), ํ•˜ํŠธ๋งŒ์ˆ˜์ˆ ์„ ๋ฐ›์€ 1๋ช…(0.2%)์ด ํฌํ•จ๋˜์—ˆ์œผ๋ฉฐ, ์ผ์‹œ์  ์žฅ๋ฃจ๋ฅผ ํ˜•์„ฑํ–ˆ๋‹ค๊ฐ€ ๋ณต์›ํ•˜์ง€ ๋ชปํ•œ 15๋ช…(2.6%), ์ฒซ ์ˆ˜์ˆ ์ดํ›„ ์žฅ๋ฃจ๋ฅผ ๋‹ค์‹œ ํ˜•์„ฑํ•œ 39๋ช…(6.8%)์„ ํฌํ•จํ•œ๋‹ค. ์˜๊ตฌ ์žฅ๋ฃจ ์ƒ์„ฑ ํ™˜์ž๋Š” ํ•ญ๋ฌธ ๊ฐ€์žฅ์ž๋ฆฌ์—์„œ ๋” ์งง์€ ์ข…์–‘ ๊ฑฐ๋ฆฌ(P < 0.001), ๋” ํฐ ์ข…์–‘ ํฌ๊ธฐ(P = 0.024) ๋ฐ ๋” ๋†’์€ ์ˆ˜์ˆ  ์ „ ๋ณ€์‹ค๊ธˆ ์ค‘์ฆ๋„ ์ง€์ˆ˜ ์ ์ˆ˜(P = 0.016)๋ฅผ ๋ณด์˜€๋‹ค. ๋‹ค๋ณ€๋Ÿ‰ ๋ถ„์„์—์„œ ํ•ญ๋ฌธ์—ฐ๋ถ€ํ„ฐ ์ข…์–‘๊นŒ์ง€ ๊ฑฐ๋ฆฌ๋Š” ์˜๊ตฌ์ ์ธ ์žฅ๋ฃจ ํ˜•์„ฑ์„ ์˜ˆ์ธกํ–ˆ์ง€๋งŒ (์ƒ๋Œ€ ์œ„ํ—˜๋„ 0.53/cm; 95% ์‹ ๋ขฐ ๊ตฌ๊ฐ„ 0.46โ€“0.60; P < 0.001), ์ˆ˜์ˆ  ์ „ ํ•ญ๋ฌธ ๊ธฐ๋Šฅ์€ ํ†ต๊ณ„์ ์œผ๋กœ ์œ ์˜ํ•˜์ง€ ์•Š์•˜๋‹ค. ๊ฒฐ๋ก : ์ง์žฅ์•” ํ™˜์ž์—์„œ ํ•ญ๋ฌธ์—ฐ๋ถ€ํ„ฐ ์ข…์–‘๊นŒ์ง€ ๊ฑฐ๋ฆฌ๋Š” ์ˆ˜์ˆ  ์ „ ์˜๊ตฌ์ ์ธ ์žฅ๋ฃจ ์ƒ์„ฑ์„ ๊ฒฐ์ •ํ•˜๋Š” ์œ ์ผํ•œ ์š”์ธ์ด์—ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๋ฐ์ดํ„ฐ๋Š” ์ค‘ํ•˜๋ถ€ ์ง์žฅ์•” ํ™˜์ž๊ฐ€ ์˜๊ตฌ ์žฅ๋ฃจ์˜ ํ•„์š”์„ฑ์„ ์ดํ•ดํ•˜๋Š” ๋ฐ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ๋‹ค.1. Introduction 1 2. Methods 2 3. Results 4 4. Discussion 7 5. References 11 Tables Table 1 16 Table 2 18 Table 3 19 Table 4 21 Table 5 23 Table 6 25 Figures Figure 1 27 Figure 2 28 Figure 3 29์„

    The effect of medial open wedge high tibial osteotomy on the patellofemoral joint: comparative analysis according to the preexisting cartilage status

    Get PDF
    BACKGROUND: Although it has been known that medial open wedge high tibial osteotomy (MOWHTO) would adversely affect the patellofemoral joint, no previous study examined the surgical outcome of MOWHTO according to the preexisting cartilage status of the patellofemoral joint. The aim of this study was to investigate the effect of MOWHTO on the patellofemoral joint with regard to objective and subjective aspects according to the preexisting cartilage status. METHODS: Ninety-two patients who underwent MOWHTO and a following second-look arthroscopic assessment were included in this study. The patients were divided into two groups according to the preexisting cartilage status of the patellofemoral joint: group 1 (International Cartilage Repair Society [ICRS] grade 2 or 3) and group 2 (ICRS grade 0 or 1). Comparative analysis was performed regarding clinical scores, radiographic parameters, and arthroscopic measurements between the two groups. RESULTS: Clinical outcomes showed overall improvement from baseline to the time of second-look operation, with no significant difference between the two groups at each time point. There were no significant differences in radiographic parameters between the two groups. Radiographic grade of patellofemoral osteoarthritis in both groups showed a tendency to progress, without statistical significance. In arthroscopic assessment, the size of the cartilage lesion on the patellofemoral joint increased with time in both groups (Pโ€‰=โ€‰0.003), but the degree of change over time between the two groups was not statistically significant. Consistently, there was no significant difference in the frequency of progression of cartilage lesion grade in the patellofemoral joint between the two groups. CONCLUSIONS: MOWHTO would contribute to osteoarthritis progression of the patellofemoral joint regardless of the preexisting cartilage status, without an association with clinical outcomes in short-term follow-up.ope

    Do Rotation and Measurement Methods Affect Reliability of Anterior Cruciate Ligament Tunnel Position on 3D Reconstructed Computed Tomography?

    Get PDF
    Background: The literature has seldom investigated the anterior cruciate ligament (ACL) tunnel position while considering the effect of rotation of 3-dimensional computed tomography (3D-CT) images during measurements. Hypothesis: We hypothesized that (1) measurement of the ACL tunnel position in the femur and tibia through use of 3D-CT is considerably influenced by rotation of the 3D model and (2) there exists a reliable measurement method for ACL tunnel position least affected by rotation. Study Design: Controlled laboratory study. Methods: The 3D-CT images of 30 randomly selected patients who underwent single-bundle ACL reconstruction were retrospectively reviewed. For femoral tunnel assessments, rectangular reference frames were used that involved the highest point of the intercondylar notch and outer margins of the lateral femoral condyle (method 1), the highest point of the intercondylar notch and outer margins of the lateral wall of the intercondylar notch (method 2), and the lowest point of the intercondylar notch and outer margins of the lateral femoral condyle (method 3). For tibial tunnel assessments, rectangular reference frames with the cortical outline at the articular surface of the tibia (method A) and the cortical outline of the proximal tibia (method B) were used. For both femoral and tibial assessments, the tunnel positions at 5ยฐ, 10ยฐ, and 15ยฐ of rotation of the 3D model were compared with that at a neutral position. Results: The values measured by methods 1 and 3 showed significant differences at greater than 5ยฐ of rotation compared with the value at the neutral position, whereas method 2 showed relatively consistent results. However, the values measured with both methods A and B showed significant differences at greater than 5ยฐ of rotation compared with the value at the neutral position. Conclusion: The tunnel position on 3D-CT images was significantly influenced by rotation during measurements. For femoral tunnel position, measurement with a reference frame using the lateral wall of the intercondylar notch (method 2) was the least affected by rotation, with relatively consistent results. Clinical Relevance: This study demonstrates that measurement using the lateral wall of the intercondylar notch might be a consistent and reliable method for evaluating the ACL femoral tunnel position considering the effect of 3D-CT image rotation during measurements. However, both methods to measure tibial tunnel position described in this study were similarly affected by rotation.ope

    Analysis of Potentially Inappropriate Medication Use and Related Factors in Terminal Cancer Patients

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ) -- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์•ฝํ•™๋Œ€ํ•™ ์•ฝํ•™๊ณผ, 2021. 2. ์ด์ฃผ์—ฐ.Polypharmacy is common in cancer patients by taking not only drugs for cancer treatment, but also drugs for other underlying diseases and supportive care drugs for relieving adverse reactions of chemotherapy. In terminal cancer patients who have 6 to 12 months of life expectancy, the goal of treatment should focus on improving quality of life, such as alleviating the pain caused by cancer-related symptoms and avoiding unnecessary treatment. Nevertheless, it is common for terminal patients to keep taking many drugs that can only benefit from long-term use. Such unnecessary polypharmacy can lead to problems such as drug interaction, adverse reactions, and poor quality of life. STOPPFrail, OncPal are the deprescribing guideline that suggest potentially inappropriate medications (PIMs) to frail patients with a limited life expectancy. The purpose of this study was to identify the frequency of PIM use according to the STOPPFrail and OncPal guideline in terminal cancer patients in South Korea and to analyze related factors. We used two data sources. The one is the data from the 2018 Health Insurance Review and Assessment Service - National Patients Sample (HIRA-NPS) of South Korea and the other was electrical medical records of cancer patients registered hospice care in 2019 at one tertiary hospital. After reviewing the STOPPFrail criteria and the OncPal guideline, we adjusted the criteria for PIMs to applicable level in this study. When we analyze the national patients sample data, patients with death records or previous medical records but no healthcare utilization for more than 6 months are considered as deceased patients. Among them, patients who used opioid analgesics or megestrol, or who had been hospitalized for more than 90 days were defined as the deceased terminal cancer patients. The prescriptions for 3 months prior to the estimated death were reviewed and only the oral medications used for more than 7 days or more were included in the analysis. For patients receiving hospice care at tertiary hospital, we reviewed the prescriptions for one months before and after the hospice consultation request date. A total of 1,558 terminal cancer patients among 1,481921 patients of 2018 national patients sample data were included for analysis. Among them, 1,133 patients (72.7%) used 5 or more medications and 630 patients (40.4%) used 10 or more medications. According to the adjusted PIM criteria, 914 patients (58.7%) used 1 or more PIMs and 210 patients (13.5%) used 3 or more PIMs. The most common categories of PIM were lipid lowering agents (307 patients, 19.7%), proton pump inhibitors (274 patients, 17.6%), hypoglycemic agents (221 patients, 14.2%), alpha-blocker for urinary symptoms (182 patients, 11.7%), H2 receptor antagonist (110 patients, 7.1%). A total of 1243 cancer patients in hospice care at the tertiary hospital were included in the analysis. Among them, 794 patients (63.9%) used 5 or more medications and 312 patients (25.1%) used 10 or more medications. Five hundred and thirty two patients (42.8%) were found that used one or more PIMs and 93 patients (7.5%) were found that used three or more PIMs. The frequent categories of PIM that found in hospice care patients were lipid lowering agents (142 patients, 11.4%), nutritional supplements (133 patients, 10.7%), multivitamins (103 patients, 10.7%), H2 receptor antagonists (95 patients, 7.6%), proton pump inhibitor (91 patients, 7.3%). This study showed that polypharmacy and PIM use according to the predefined guideline in terminal cancer patients were prevalent in real-world practice. These findings suggested that active interventions for pharmacotherapy were necessary for these patients.์•”ํ™˜์ž๋Š” ์•” ์น˜๋ฃŒ์— ๋Œ€ํ•œ ์•ฝ์ œ๋ฟ ์•„๋‹ˆ๋ผ, ๋‹ค๋ฅธ ๊ธฐ์ €์งˆํ™˜์— ๋Œ€ํ•œ ์น˜๋ฃŒ์ œ์™€ ํ•ญ์•”์น˜๋ฃŒ์— ๋”ฐ๋ฅธ ๋ถ€์ž‘์šฉ ์ฆ์ƒ ์™„ํ™”๋ฅผ ์œ„ํ•œ ๋ณด์กฐ์•ฝ์ œ ๋“ฑ์„ ํ•จ๊ป˜ ํˆฌ์•ฝํ•˜์—ฌ ๋‹ค์•ฝ์ œ ์‚ฌ์šฉ์˜ ๋นˆ๋„๊ฐ€ ๋†’๋‹ค. ๋ง๊ธฐ ์•”ํ™˜์ž๋Š” ์•”์˜ ์ข…๋ฅ˜๋‚˜ ํ™˜์ž์˜ ์ž„์ƒ ์ƒํƒœ์— ๋”ฐ๋ผ 6๊ฐœ์›”์—์„œ 12๊ฐœ์›”์˜ ์—ฌ๋ช…์ด ์˜ˆ์ƒ๋˜๋Š”๋ฐ, ์ด๋Ÿฌํ•œ ์ƒํ™ฉ์—์„œ ์น˜๋ฃŒ๋Š” ์•” ๊ด€๋ จ๋œ ์ฆ์ƒ์œผ๋กœ ์ธํ•œ ๊ณ ํ†ต์„ ์™„ํ™”ํ•˜๊ณ  ๋ถˆํ•„์š”ํ•œ ์น˜๋ฃŒ๋ฅผ ํ”ผํ•˜๋Š” ๊ฒƒ๊ณผ ๊ฐ™์ด ์‚ถ์˜ ์งˆ์„ ํ–ฅ์ƒ์‹œํ‚ค๋Š”๋ฐ ์ค‘์ ์„ ๋‘์–ด์•ผ ํ•œ๋‹ค. ๊ทธ๋Ÿผ์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ  ๋ง๊ธฐ ํ™˜์ž์—์„œ ์žฅ๊ธฐ๊ฐ„ ๋ณต์šฉํ•ด์•ผ ์ด์ต์„ ์–ป์„ ์ˆ˜ ์žˆ๋Š” ์•ฝ๋ฌผ์˜ ๋ณต์šฉ์„ ์œ ์ง€ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ํ”ํ•œ๋ฐ, ์ด๋Ÿฌํ•œ ๋ถˆํ•„์š”ํ•œ ๋‹ค์•ฝ์ œ ์‚ฌ์šฉ์œผ๋กœ ์ธํ•ด ์•ฝ๋ฌผ์ƒํ˜ธ์ž‘์šฉ, ์•ฝ๋ฌผ ๋ถ€์ž‘์šฉ, ํ™˜์ž ์‚ถ์˜ ์งˆ ์ €ํ•˜ ๋“ฑ์˜ ๋ฌธ์ œ๊ฐ€ ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ๋‹ค. Deprescribing์€ ๋” ์ด์ƒ ์œ ์ต์„ฑ์ด ์—†๊ฑฐ๋‚˜ ์œ„ํ•ด๋ฅผ ์•ผ๊ธฐ์‹œํ‚ฌ ์ˆ˜ ์žˆ๋Š” ์•ฝ์˜ ์šฉ๋Ÿ‰์„ ๊ฐ๋Ÿ‰ํ•˜๊ฑฐ๋‚˜ ์ค‘๋‹จํ•˜๋Š” ๊ณผ์ •์ด๋ฉฐ, STOPPFrail, OncPal์€ ๊ธฐ๋Œ€์—ฌ๋ช…์ด ์–ผ๋งˆ ๋‚จ์ง€ ์•Š์€ ๋…ธ์‡ ํ•œ ํ™˜์ž์—๊ฒŒ ์ž ์žฌ์ ์œผ๋กœ ๋ถ€์ ์ ˆํ•œ ์•ฝ๋ฌผ(potentially inappropriate medication, PIM)์„ ์ œ์‹œํ•œ deprescribing ๊ฐ€์ด๋“œ๋ผ์ธ์ด๋‹ค. ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” ํ•œ๊ตญ์˜ ๋ง๊ธฐ ์•”ํ™˜์ž์—์„œ STOPPFrail, OncPal ๊ฐ€์ด๋“œ๋ผ์ธ์— ๋”ฐ๋ฅธ ์ž ์žฌ์  ๋ถ€์ ์ ˆ ์•ฝ๋ฌผ์˜ ์‚ฌ์šฉ ํ˜„ํ™ฉ์„ ํŒŒ์•…ํ•˜๊ณ  ๊ด€๋ จ ์ธ์ž๋ฅผ ๋ถ„์„ํ•˜๊ณ ์ž ํ•˜์˜€๋‹ค. 2018๋…„ ๊ฑด๊ฐ•๋ณดํ—˜์‹ฌ์‚ฌํ‰๊ฐ€์› ์ฒญ๊ตฌ์ž๋ฃŒ์™€ 2019๋…„ ์„œ์šธ๋Œ€ํ•™๊ต๋ณ‘์›์—์„œ ํ˜ธ์Šคํ”ผ์Šค ์ƒ๋‹ด ์˜๋ขฐ๋œ ์•”ํ™˜์ž์˜ ์ฒ˜๋ฐฉ๋‚ด์—ญ์„ ๋ถ„์„ํ•˜์˜€๋‹ค. ์ผ์ฐจ์ ์œผ๋กœ ์ž ์žฌ์  ๋ถ€์ ์ ˆ ์•ฝ๋ฌผ์€ STOPPFrail, OncPal ๊ฐ€์ด๋“œ๋ผ์ธ์˜ ํ•ญ๋ชฉ์„ ์ข…ํ•ฉํ•˜์—ฌ ๋ณธ ์—ฐ๊ตฌ์—์„œ ์ ์šฉ ๊ฐ€๋Šฅํ•œ ๊ธฐ์ค€์œผ๋กœ ์ˆ˜์ •ํ•˜์—ฌ ์„ ์ •ํ•˜์˜€๋‹ค. ์ „๊ตญ๋ฏผ ํ‘œ๋ณธ์ž๋ฃŒ์—์„œ๋Š” ์•”ํ™˜์ž ์ค‘์—์„œ ์‚ฌ๋ง ๊ธฐ๋ก์ด ์žˆ๊ฑฐ๋‚˜ ์ด์ „์— ์ง„๋ฃŒ๊ธฐ๋ก์ด ์žˆ์—ˆ์œผ๋‚˜ 6๊ฐœ์›” ์ด์ƒ ์ฒญ๊ตฌ ๋‚ด์—ญ์ด ์—†๋Š” ํ™˜์ž๋ฅผ ์‚ฌ๋งํ•œ ํ™˜์ž๋กœ ๊ฐ„์ฃผํ•˜๊ณ , ์ด ์ค‘์—์„œ ๋งˆ์•ฝ์„ฑ ์ง„ํ†ต์ œ๋‚˜ ์‹์š•์ด‰์ง„์ œ์ธ megestrol์„ ์‚ฌ์šฉํ•œ ๊ธฐ๋ก์ด ์žˆ๊ฑฐ๋‚˜ 90์ผ ์ด์ƒ ์ž…์›ํ•œ ๊ธฐ๋ก์ด ์žˆ๋Š” ํ™˜์ž๋ฅผ ๋ง๊ธฐ ์•”ํ™˜์ž ์‚ฌ๋งํ•œ ๊ฒƒ์œผ๋กœ ์ •์˜ํ•˜์˜€๋‹ค. ์‚ฌ๋ง ์ „ 3๊ฐœ์›” ๊ฐ„์˜ ์ฒ˜๋ฐฉ์„ ๋ถ„์„ํ•˜์˜€์œผ๋ฉฐ, 7์ผ ์ด์ƒ ์‚ฌ์šฉํ•œ ๊ฒฝ๊ตฌ์•ฝ ์ฒ˜๋ฐฉ์„ ๋ถ„์„ํ•˜์˜€๋‹ค. ์„œ์šธ๋Œ€ํ•™๊ต๋ณ‘์› ํ˜ธ์Šคํ”ผ์Šค ํ™˜์ž ์ž๋ฃŒ์—์„œ๋Š” ํ˜ธ์Šคํ”ผ์Šค ์ƒ๋‹ด ์˜๋ขฐ์ผ์„ ๊ธฐ์ค€์œผ๋กœ, ์ด์ „ ๋ฐ ์ดํ›„ ํ•œ ๋‹ฌ ๊ฐ„์˜ ์ฒ˜๋ฐฉ๋‚ด์—ญ์—์„œ ์ž ์žฌ์  ๋ถ€์ ์ ˆ ์•ฝ๋ฌผ์„ ๋ถ„์„ํ•˜์˜€๋‹ค. 2018๋…„ ์ „๊ตญ๋ฏผ ํ‘œ๋ณธ์ž๋ฃŒ์˜ ์ด 1,481,921๋ช… ์ค‘ ๋ง๊ธฐ ์•”ํ™˜์ž๋กœ ์ถ”์ •๋˜๋Š” 1,558๋ช…์˜ ์ฒ˜๋ฐฉ์„ ๋ถ„์„ํ•œ ๊ฒฐ๊ณผ, 1,133๋ช…(72.7%)์ด 5์ข… ์ด์ƒ ์•ฝ๋ฌผ์„ ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๊ณ  ์ด ์ค‘ 630๋ช…(40.4%)๋Š” 10์ข… ์ด์ƒ์˜ ์•ฝ๋ฌผ์„ ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ๋ฏธ๋ฆฌ ์ •์˜ํ•œ PIM์„ ํ•˜๋‚˜ ์ด์ƒ ์‚ฌ์šฉํ•œ ๊ฒƒ์œผ๋กœ ํ™•์ธ๋œ ํ™˜์ž๋Š” 914๋ช…์œผ๋กœ ์ „์ฒด์˜ 58.7%๋ฅผ ์ฐจ์ง€ํ•˜์˜€์œผ๋ฉฐ, 3์ข… ์ด์ƒ ์‚ฌ์šฉํ•œ ํ™˜์ž๋Š” 210๋ช…(13.5%)์ด์—ˆ๋‹ค. ๊ฐ€์žฅ ํ”ํ•œ PIM์€ ์ด์ƒ์ง€์งˆํ˜ˆ์ฆ ์น˜๋ฃŒ์ œ(307๋ช…, 19.7%), ํ”„๋กœํ†คํŽŒํ”„์–ต์ œ์ œ(274๋ช…, 17.6%), ํ˜ˆ๋‹น๊ฐ•ํ•˜์ œ(221๋ช…, 14.2%), ์•ŒํŒŒ์ฐจ๋‹จ์ œ(์ „๋ฆฝ์„  ๋น„๋Œ€์ฆ์— ๋Œ€ํ•œ, 182๋ช…, 11.7%), H2-์ˆ˜์šฉ์ฒด์ฐจ๋‹จ์ œ(110๋ช…, 7.1%) ์ˆœ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. 2019๋…„ ์„œ์šธ๋Œ€ํ•™๊ต๋ณ‘์› ํ˜ธ์Šคํ”ผ์Šค ์ƒ๋‹ด ์˜๋ขฐ๋œ ์•”ํ™˜์ž ์ด 1,243๋ช…์„ ๋ถ„์„ํ•œ ๊ฒฐ๊ณผ, 794๋ช…(63.9%)์ด 5์ข… ์ด์ƒ ์•ฝ๋ฌผ์„ ๋™์‹œ์— ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๊ณ  ์ด ์ค‘ 312๋ช…(25.1%)๋Š” 10์ข… ์ด์ƒ ๋‹ค์•ฝ์ œ๋ฅผ ์‚ฌ์šฉํ•˜์˜€๋‹ค. PIM์„ ํ•˜๋‚˜ ์ด์ƒ ์‚ฌ์šฉํ•œ ๊ฒƒ์œผ๋กœ ํ™•์ธ๋œ ํ™˜์ž๋Š” 532๋ช…(42.8%)์˜€๊ณ , 93๋ช…(7.5%)์—์„œ๋Š” 3์ข… ์ด์ƒ์˜ PIMs๋ฅผ ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ™•์ธ๋˜์—ˆ๋‹ค. ๊ธฐ๋Œ€์—ฌ๋ช…์ด ์งง์€ ์•”ํ™˜์ž์—์„œ ๊ฐ€์žฅ ํ”ํžˆ ์‚ฌ์šฉ๋œ PIM์˜ ๊ณ„์—ด์€ ์ด์ƒ์ง€์งˆํ˜ˆ์ฆ ์น˜๋ฃŒ์ œ(142๋ช…, 11.4%), ์˜์–‘์ œ(133๋ช…, 10.7%), ์ข…ํ•ฉ ๋น„ํƒ€๋ฏผ์ œ(103๋ช…, 8.3%), H2 ์ˆ˜์šฉ์ฒด ์ฐจ๋‹จ์ œ(95๋ช…, 7.6%), ํ”„๋กœํ†คํŽŒํ”„์–ต์ œ์ œ(91๋ช…, 7.3%) ์ˆœ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ๋ณธ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ, ์šฐ๋ฆฌ๋‚˜๋ผ ์ž„์ƒ ํ˜„์‹ค์—์„œ ์—ฌ๋ช…์ด ๊ธธ์ง€ ์•Š์€ ๋ง๊ธฐ ์•”ํ™˜์ž์—์„œ ์‹ค์ œ๋กœ ๋‹ค์•ฝ์ œ ์‚ฌ์šฉ๊ณผ deprescribing์˜ ๋Œ€์ƒ์œผ๋กœ ๊ฒ€ํ† ๊ฐ€ ํ•„์š”ํ•œ ์ž ์žฌ์  ๋ถ€์ ์ ˆ ์•ฝ๋ฌผ์˜ ์‚ฌ์šฉ์ด ๋นˆ๋ฒˆํ•จ์„ ํ™•์ธํ•  ์ˆ˜ ์žˆ์—ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋Š” ์ด๋“ค ํ™˜์ž ๋Œ€์ƒ์œผ๋กœ ์•ฝ๋ฌผ์น˜๋ฃŒ์— ๋Œ€ํ•œ ๊ฒ€ํ†  ๋ฐ ์ค‘์žฌ๊ฐ€ ํ•„์š”ํ•จ์„ ์‹œ์‚ฌํ•œ๋‹ค.1. ์„œ๋ก  1 1.1 ์—ฐ๊ตฌ์˜ ๋ฐฐ๊ฒฝ 1 1.2 ์—ฐ๊ตฌ์˜ ํ•„์š”์„ฑ 5 1.3 ์—ฐ๊ตฌ์˜ ๋ชฉ์  7 2. ์—ฐ๊ตฌ ๋ฐฉ๋ฒ• 8 2.1 ์—ฐ๊ตฌ ์ž๋ฃŒ 8 2.2 ์—ฐ๊ตฌ ๋Œ€์ƒ 11 2.3 ๋ถ„์„ ๊ธฐ๊ฐ„ ์„ค์ • 33 2.4 ๊ฒฐ๊ณผ ๋ณ€์ˆ˜ 35 2.5 PIM ๋ฐœ์ƒ ๋นˆ๋„ ๊ด€๋ จ ์ธ์ž ๋ถ„์„ 35 2.6 ํ†ต๊ณ„ ๋ถ„์„ 35 3. ์—ฐ๊ตฌ ๊ฒฐ๊ณผ 36 3.1 ์—ฐ๊ตฌ ๋Œ€์ƒ์ž ์„ ์ • ๋ฐ ๊ธฐ์ดˆ ํŠน์„ฑ ํŒŒ์•… 36 3.2 ๋‹จ์ผ ์ƒ๊ธ‰์ข…ํ•ฉ๋ณ‘์› ์ž๋ฃŒ์—์„œ PIM ๋ฐœ์ƒ ๋นˆ๋„ ๋ถ„์„ 42 3.3 ๊ฑด๊ฐ•๋ณดํ—˜์‹ฌ์‚ฌํ‰๊ฐ€์› ์ž๋ฃŒ์—์„œ PIM ๋ฐœ์ƒ ๋นˆ๋„ ๋ถ„์„ 47 3.4 ์ƒ๊ธ‰์ข…ํ•ฉ๋ณ‘์› ์ž๋ฃŒ์—์„œ PIM ๋ฐœ์ƒ ๋นˆ๋„ ๊ด€๋ จ์ธ์ž ๋ถ„์„ 51 3.5 ์‹ฌํ‰์› ํ‘œ๋ณธ ์ž๋ฃŒ์—์„œ PIM ๋ฐœ์ƒ ๋นˆ๋„ ๊ด€๋ จ์ธ์ž ๋ถ„์„ 54 4. ๊ณ ์ฐฐ 58 5. ๊ฒฐ๋ก  69Maste

    Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis: A double-blinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, non-inferiority clinical trial

    Get PDF
    Introduction: At present, information about clinical efficacy and adverse events of controlled release (CR) form of pelubiprofen, a prodrug of 2-arylopropionic acid with relatively selective effects on cyclooxygenase-2 activity, remains scarce. In this study, we sought to determine non-inferiority of pelubiprofen CR 90 mg/day compared to aceclofenac 200 mg/day regarding clinical efficacy and adverse events after a 4-week course of medication in the patients with symptomatic knee osteoarthritis. Materials and methods: A total of 191 patients were randomly assigned to take either pelubiprofen CR 90 mg (n = 95) or aceclofenac 200 mg (n = 96). The primary outcome variable was non-inferiority of pain reduction between baseline and week 4 when assessed using a 100 mm pain visual analogue scale (VAS). Pelubiprofen was considered non-inferior to aceclofenac if the upper limit of the one-sided 97.5% confidence interval for the difference in terms of pain VAS was above 15 mm (the average change of pain VAS in the pelubiprofen group-pain VAS reduction in the aceclofenac group). Secondary outcome variables were the changes in 100 mm pain VAS at week 2 versus baseline, K-Western Ontario, and McMaster University Arthritis Index (K-WOMAC) changes at weeks 2 and 4 as compared to baseline, patient global assessment at weeks 2 and 4. The frequency and amount of rescue medicine usage at weeks 2 and 4 were also evaluated as the secondary outcome variable. For safety analysis, adverse events, clinical laboratory tests, vital signs, and physical examinations were assessed and conducted at each follow-up visit. Results: At week 4, the pain VAS values were significantly reduced in both groups receiving either pelubiprofen CR 90 mg or aceclofenac 200 mg as compared to the baseline. However, the pelubiprofen group and the aceclofenac group respectively showed the pain VAS changes of -22 and -21.9 in the pre-protocol set and -20.8 and -21.7 in the full analysis set, confirming non-inferiority. The pelubiprofen CR 90 mg showed a reduced incidence of adverse events compared to the aceclofenac 200 mg (p = 0.005). Conclusions: Pelubiprofen CR 90 mg is as effective as aceclofenac 200 mg with reduced adverse events for the treatment of symptomatic knee osteoarthritis.ope

    In Vivo Evaluation of the Subject-Specific Finite Element Model for Knee Joint Cartilage Contact Area

    Get PDF
    In this paper, we present a new validation method for subject-specific finite element (FE) modeling of the knee joint based on in vivo computed tomography (CT) and magnetic resonance imaging (MRI) data. Previously, several FE models have been developed for estimating the mechanical response of joint structures, where direct or indirect in vivo measurement is difficult or impossible. More recently, studies using MRI have provided clear visualization of the motion and deformation of the articular cartilage within the tibiofemoral (TF) joint space. Two methods have been introduced to validate in vivo subject-specific models: alignment of supine MRI with X-ray images and weight-bearing MRI. The size of the contact area between the femur and tibia was determined by computing the area of femoral cartilage that intersected the tibial cartilage. The result showed good agreement between non-weight bearing image aligned with X-ray and weight-bearing MRI images. This study may help to better define the relative importance of modeling validations for the development of subject-specific models.ope

    The effects of posterior cruciate ligament deficiency on posterolateral corner structures under gait- and squat-loading conditions: A computational knee model

    Get PDF
    OBJECTIVES: The aim of the current study was to analyse the effects of posterior cruciate ligament (PCL) deficiency on forces of the posterolateral corner structure and on tibiofemoral (TF) and patellofemoral (PF) contact force under dynamic-loading conditions. METHODS: A subject-specific knee model was validated using a passive flexion experiment, electromyography data, muscle activation, and previous experimental studies. The simulation was performed on the musculoskeletal models with and without PCL deficiency using a novel force-dependent kinematics method under gait- and squat-loading conditions, followed by probabilistic analysis for material uncertain to be considered. RESULTS: Comparison of predicted passive flexion, posterior drawer kinematics and muscle activation with experimental measurements showed good agreement. Forces of the posterolateral corner structure, and TF and PF contact forces increased with PCL deficiency under gait- and squat-loading conditions. The rate of increase in PF contact force was the greatest during the squat-loading condition. The TF contact forces increased on both medial and lateral compartments during gait-loading conditions. However, during the squat-loading condition, the medial TF contact force tended to increase, while the lateral TF contact forces decreased. The posterolateral corner structure, which showed the greatest increase in force with deficiency of PCL under both gait- and squat-loading conditions, was the popliteus tendon (PT). CONCLUSION: PCL deficiency is a factor affecting the variability of force on the PT in dynamic-loading conditions, and it could lead to degeneration of the PF joint.Cite this article: K-T. Kang, Y-G. Koh, M. Jung, J-H. Nam, J. Son, Y.H. Lee, S-J. Kim, S-H. Kim. The effects of posterior cruciate ligament deficiency on posterolateral corner structures under gait- and squat-loading conditions: A computational knee model. Bone Joint Res 2017;6:31-42. DOI: 10.1302/2046-3758.61.BJR-2016-0184.R1.ope

    Development of Hybrid Electrochemical Water Treatment System Combined of Deionization and Oxidation

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ํ™”ํ•™์ƒ๋ฌผ๊ณตํ•™๋ถ€, 2017. 2. ์œค์ œ์šฉ.Over recent decades, the lack of available water has been considered as a critical challenge for mankind. Electrochemical water treatment can be a promising alternative due to its high energy efficiency, eco-friendliness and lack of required hazardous chemicals. Capacitive deionization (CDI), electrodialysis (ED) and desalination battery are well-established demonstrations that are successfully converged of materials used for energy storage with electrochemical system for water treatment. These demonstrations accomplish electrochemical deionization by means of the operational principle of energy storage in energy storage systems (e.g., supercapacitors and batteries). Although they provide an energy efficient deionization process, the systems have suffered from the limitations in their systems and materials, attributing to difficulties to find suitable compounds/systems for capturing anions and retain the stability of active material in aqueous system. In this dissertation, it is demonstrated that a novel electrochemical water treatment system combined of deionization and oxidation, and suitable materials for intercalation/deintercalation of cations. First of all, a novel hybrid electrochemical water treatment system consisting of an electrochemical desalination system synchronized with an oxidation process is developed. The hybrid electrochemical water treatment system consists of electrode material for the sodium ion battery as a desalination component and an oxidant generation anode serving the oxidation function. As a primary result, superior desalination capacities of approximately 87 mg g-1 and 36 mg g-1 were accomplished with NaCl concentrations of 35 g L-1 and 3 g L-1, respectively. Moreover, this hybrid system showed a coulombic efficiency in synthetic brackish water (2.79 g L-1 of diverse ions) of approximately 98% and 66% for desalination and oxidation, respectively. Second, a new HCDI system with sodium iron pyrophosphate (Na2FeP2O7) is investigated. The overall deionization performance of Na2FeP2O7 as the electrode capturing cations is demonstrated. The major results of the HCDI system with Na2FeP2O7 showed a superior maximum deionization rate performance (0.08 mg g-1 s-1) with a comparable deionization capacity (30.2 mg g-1) compared to the previous HCDI system with Na4Mn9O18. Furthermore, the analysis of the CDI Ragone plot was applied to investigate the hybrid behavior characteristics, high deionization capacity that originated from the high capacity of Na2FeP2O7 and fast deionization rates resulting from the supercapacitor. Consequently, the novel electrochemical water treatment and electrode materials can contribute to providing a new strategy to overcome the limitations of materials used for capturing anions and discovering their behavior for electrochemical water treatment.1. Introduction 1 1.1. Research Background 1 1.2. Objectives 5 2. Literature Review 7 2.1. Electrochemical Water Treatment System 7 2.1.1. Capacitive Deionization 7 2.1.2. Desalination Battery 16 2.1.3. Hybrid Capacitive Deionization 20 2.2. Materials of Electrochemical Water Treatment for Deionization and Oxidation 24 2.2.1. Materials for Deionization 24 3. Hybrid Electrochemical Water Treatment System for Deionization and Oxidation 33 3.1. Introduction 33 3.2. Experimental 38 3.2.1. Preparation of sodium manganese oxide (Na0.44MnO2) 38 3.2.2. Preparation of blue TiO2 nanotube on meshed Ti substrate (m-Blue TiO2 NTs) 39 3.2.3. Characterization of prepared electrodes 40 3.2.4. Operations of the hybrid system for deionization and oxidant generation 41 3.3. Results and Discussion 43 3.4. Summary 67 4. Na2FeP2O7 as Novel Material for Hybrid Capacitive Deionization 68 4.1. Introduction 68 4.2. Experimental 71 4.2.1. Material synthesis 71 4.2.2. Electrode fabrication 72 4.2.3. Electrochemical characterization 73 4.2.4. Deionization test 74 4.3. Results and Discussion 76 4.4. Summary 98 5. Conclusion 99 References 101 ๊ตญ๋ฌธ์ดˆ๋ก 114Docto

    A Study on Energy Harvesting using Kelvin Water Dropper

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์ „๊ธฐยท์ปดํ“จํ„ฐ๊ณตํ•™๋ถ€, 2015. 8. ๊น€์šฉ๊ถŒ.๋ณธ ๋…ผ๋ฌธ์—์„œ๋Š” ์†Œ๋Ÿ‰์˜ ๋ฌผ๋กœ๋„ ๊ณ ์ „์••์˜ ์ •์ „๊ธฐ๋ฅผ ๋ฐœ์ƒ์‹œํ‚ค๋Š” Kelvin water dropper๋ฅผ ์—๋„ˆ์ง€ ํ•˜๋ฒ ์ŠคํŒ…์— ์ด์šฉํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ๊ณ ์ „์•• ์ € ์ „ํ•˜์˜ ์ •์ „๊ธฐ ์—๋„ˆ์ง€๋ฅผ ์ €์žฅํ•  ์ˆ˜ ์žˆ๋Š” ์—๋„ˆ์ง€ ์ €์žฅ ํšŒ๋กœ๋ฅผ ์ œ์•ˆํ•˜๊ณ  Kelvin water dropper๋ฅผ ์ด์šฉํ•œ ์—๋„ˆ์ง€ ํ•˜๋ฒ ์ŠคํŒ… ์‹œ์Šคํ…œ์˜ ํšจ์œจ์„ ์ฆ๋Œ€์‹œํ‚ค๊ธฐ ์œ„ํ•œ ๋‘ ๊ฐ€์ง€ ๋ฐฉ๋ฒ•์„ ์ œ์‹œํ•˜์˜€๋‹ค. ๋˜ํ•œ ์ด๋Ÿฌํ•œ ์‹œ์Šคํ…œ์ด ๊ฐ€๋ณ€์ ์ธ ํ™˜๊ฒฝ์—์„œ๋„ ํŠน์ • ์‘์šฉ์— ๋งž๋Š” ์ผ์ •ํ•œ ์ถœ๋ ฅ ์ „์••์„ ๋‚ผ ์ˆ˜ ์žˆ๋„๋ก ์ „์›๊ณต๊ธ‰ ํšŒ๋กœ๋ฅผ ๋„์ž…ํ•˜์˜€๋‹ค. Kelvin water dropper๊ฐ€ ์•ˆ์ •์ ์ด๊ณ  ํšจ์œจ์ ์œผ๋กœ ๋™์ž‘ํ•˜๋„๋ก Kelvin water dropper๋ฅผ ์ˆ˜ํ•™์ ์œผ๋กœ ๋ชจ๋ธ๋งํ•˜์—ฌ ์ ํ•ฉํ•œ ๋ฐฐ์น˜์— ๋Œ€ํ•œ ์‹œ๋ฎฌ๋ ˆ์ด์…˜ ๋ฐ ์‹คํ—˜์„ ์ง„ํ–‰ํ•˜์—ฌ ๊ธˆ์† ์šฉ๊ธฐ์™€ ๊ธˆ์† ๋ง ์‚ฌ์ด์˜ ๊ฑฐ๋ฆฌ h ๋ฅผ 3 cm ๋กœ ์ •ํ•˜์˜€๋‹ค. ๋‹ค์Œ์œผ๋กœ Kelvin water dropper์—์„œ ๋ฐœ์ƒ๋˜๋Š” ์ •์ „๊ธฐ ์—๋„ˆ์ง€๋ฅผ ์ €์žฅํ•˜๊ธฐ ์œ„ํ•ด MEMS ์Šค์œ„์น˜๋ฅผ ์ด์šฉํ•œ ์—๋„ˆ์ง€ ์ €์žฅํšŒ๋กœ๋ฅผ ์ œ์ž‘ ๋ฐ ์‹œํ—˜ํ•˜์˜€์œผ๋‚˜ ์ ํ•ฉ์„ฑ์˜ ๋ฌธ์ œ์™€ ํšจ์œจ์„ฑ์˜ ๋ฌธ์ œ๋กœ ๋ถˆ๊ฝƒ ๋ฐฉ์ „ ๊ฐ„๊ทน์„ ์ด์šฉํ•œ ์—๋„ˆ์ง€ ์ €์žฅ ํšŒ๋กœ๋ฅผ ์ƒˆ๋กœ์ด ์„ค๊ณ„ ๋ฐ ์‹œํ—˜ํ•˜์˜€๋‹ค. ์ œ์ž‘๋œ ์—๋„ˆ์ง€ ์ €์žฅ ํšŒ๋กœ๋ฅผ ์ด์šฉํ•˜์—ฌ Kelvin water dropper์—์„œ ํ•˜๋ฒ ์ŠคํŒ…์„ ์ง„ํ–‰ํ•˜์˜€์„ ๊ฒฝ์šฐ ๋ฆฌํ„ฐ๋‹น 32.56 ฮผJ ์˜ ์—๋„ˆ์ง€๋ฅผ ์ˆ˜ํ™•ํ•  ์ˆ˜ ์žˆ์—ˆ๋‹ค. ๋” ๋‚˜์•„๊ฐ€ ์‹œ์Šคํ…œ์˜ ํšจ์œจ ํ–ฅ์ƒ์„ ์œ„ํ•ด Paschen์˜ ๋ฒ•์น™์— ๊ทผ๊ฑฐํ•œ ๋ถˆ๊ฝƒ ๋ฐฉ์ „ ๊ฐ„๊ทน์„ ์ฆ๊ฐ€์‹œํ‚ด์œผ๋กœ์จ ์—๋„ˆ์ง€ ์ €์žฅ ํšจ์œจ์„ ์ฆ๊ฐ€์‹œํ‚ฌ ์ˆ˜ ์žˆ์—ˆ๋Š”๋ฐ ๋ฐฉ์ „๊ฐ„๊ทน์ด 3 mm ์ดํ•˜์ผ ๋•Œ์—๋Š” ์—๋„ˆ์ง€ ์ €์žฅ ํšจ์œจ์ด ์ฆ๊ฐ€ํ•˜๋Š” ๊ฒฝํ–ฅ์„ ์‹คํ—˜์„ ํ†ตํ•ด ํ™•์ธํ•  ์ˆ˜ ์žˆ์—ˆ์œผ๋‚˜ 3 mm ๋ฅผ ์ดˆ๊ณผํ•œ ์‹œ์ ์—์„œ๋Š” ๋ฌผ๋ฐฉ์šธ ์‚ฌ์ด์˜ ๋ฐ˜๋ฐœ๋กœ ์ธํ•œ ๋ฌผ์˜ ์†์‹ค๋กœ ํšจ์œจ์ด ๊ฐ์†Œํ•จ์„ ํ™•์ธํ•˜์˜€๋‹ค. ๋˜ํ•œ Kelvin water dropper์˜ ์ „์•• ์ƒ์Šน์‹์—์„œ ์ดˆ๋‹น ๋–จ์–ด์ง€๋Š” ๋ฌผ๋ฐฉ์šธ์˜ ์ˆ˜๋ฅผ ์ฆ๊ฐ€์‹œํ‚ค๊ธฐ ์œ„ํ•ด ๋‹ค์ค‘ ๋…ธ์ฆ์„ ๋„์ž…ํ•˜์˜€๊ณ  ๊ทธ ๊ฒฐ๊ณผ ๋…ธ์ฆ์˜ ๊ฐœ์ˆ˜๋งŒํผ์˜ ์—๋„ˆ์ง€ ์ถฉ์ „์‹œ๊ฐ„์ด ๊ฐ์†Œํ•˜์˜€๋‹ค. ์ด๋Ÿฌํ•œ ๋ชจ๋“  ๊ฒฐ๊ณผ๋“ค์„ ์ข…ํ•ฉํ•˜์—ฌ 3 V ์˜ ์ถœ๋ ฅ ์ „์••์„ ๋‚ผ ์ˆ˜ ์žˆ๋Š” ์ „์› ๊ณต๊ธ‰ ํšŒ๋กœ๋ฅผ ์ถ”๊ฐ€ํ•˜์˜€๊ณ , ์ด 5.84 L ์˜ ๋ฌผ์„ ์‚ฌ์šฉํ•˜์—ฌ 3 V ์˜ ์ถœ๋ ฅ ์ „์••์ด 1 Mฮฉ ์˜ ๋ถ€ํ•˜๋ฅผ ํ†ตํ•ด 1 s ๋™์•ˆ ์œ ์ง€ํ•˜๋Š” ๊ฒฐ๊ณผ๋ฅผ ์–ป์Œ์œผ๋กœ์จ ์‹œ์Šคํ…œ์˜ ์œ ํšจ์„ฑ์„ ํ™•์ธํ•˜์˜€๋‹ค. ์ œ์•ˆ๋œ Kelvin water dropper๋ฅผ ์ด์šฉํ•œ ์—๋„ˆ์ง€ ํ•˜๋ฒ ์ŠคํŒ… ์‹œ์Šคํ…œ์€ ์ ์€ ์–‘์˜ ๋ฌผ๋กœ๋„ ๋ฐœ์ „์ด ๊ฐ€๋Šฅํ•œ ์นœํ™˜๊ฒฝ ์—๋„ˆ์ง€์›์œผ๋กœ ๋‹ค์–‘ํ•œ ํ™˜๊ฒฝ์—์„œ์˜ ์—๋„ˆ์ง€ ์ˆ˜ํ™•์— ๊ทธ ๋ถ„์•ผ๋ฅผ ํ™•์žฅํ•  ์ˆ˜ ์žˆ์„ ๊ฒƒ์œผ๋กœ ๊ธฐ๋Œ€๋œ๋‹ค.์ดˆ๋ก ๋ชฉ์ฐจ ์ œ 1 ์žฅ ์„œ ๋ก  1 1.1 ์—ฐ๊ตฌ์˜ ๋ฐฐ๊ฒฝ 1 1.2 ์—๋„ˆ์ง€ ํ•˜๋ฒ ์ŠคํŒ…์˜ ์—ฐ๊ตฌ ๋™ํ–ฅ 4 1.3 Kelvin water dropper 14 1.4 ์—ฐ๊ตฌ์˜ ๋™๊ธฐ ๋ฐ ๋ชฉ์  15 1.5 ๋…ผ๋ฌธ์˜ ๊ตฌ์„ฑ 17 ์ œ 2 ์žฅ Kelvin water dropper์˜ ์ด๋ก ์  ๋ถ„์„๊ณผ ๊ตฌ์„ฑ 19 2.1 Kelvin water dropper์˜ ์›๋ฆฌ 19 2.2 Kelvin water dropper์˜ ๊ตฌ์„ฑ 24 ์ œ 3 ์žฅ ์ •์ „๊ธฐ ์—๋„ˆ์ง€๋ฅผ ์ €์žฅํ•˜๊ธฐ์œ„ํ•œ ์—๋„ˆ์ง€ ์ €์žฅํšŒ๋กœ์˜ ์„ค๊ณ„์™€ ์ œ์ž‘ 30 3.1 Paschen๊ณก์„ ์— ์˜ํ•œ ๊ณต๊ธฐ์˜ ์ ˆ์—ฐ ํŒŒ๊ดด ์ „์•• 30 3.1.1 Paschen์˜ ๋ฒ•์น™ 30 3.1.2 ์ˆ˜์ •๋œ Paschen์˜ ๋ฒ•์น™ 36 3.2 ์—๋„ˆ์ง€ ์ €์žฅํšŒ๋กœ์˜ ์„ค๊ณ„ 38 3.2.1 MEMS switch๋ฅผ ์ด์šฉํ•œ ์—๋„ˆ์ง€ ์ €์žฅํšŒ๋กœ 38 3.2.2 ๋ถˆ๊ฝƒ ๋ฐฉ์ „ ๊ฐ„๊ทน์„ ์ด์šฉํ•œ ์—๋„ˆ์ง€ ์ €์žฅํšŒ๋กœ 42 ์ œ 4 ์žฅ ์‹œ์Šคํ…œ์˜ ํšจ์œจ ํ–ฅ์ƒ ๋ฐฉ๋ฒ•๊ณผ ์ „์›๊ณต๊ธ‰ ํšŒ๋กœ์˜ ์ œ์ž‘ 47 4.1 ์‹œ์Šคํ…œ ํšจ์œจ ํ–ฅ์ƒ ๋ฐฉ๋ฒ• 47 4.1.1 ๋ถˆ๊ฝƒ ๋ฐฉ์ „ ๊ฐ„๊ทน 47 4.1.2 ๋‹ค์ค‘ ๋…ธ์ฆ 55 4.2 ์ „์›๊ณต๊ธ‰ ํšŒ๋กœ์˜ ์ œ์ž‘ 59 ์ œ 5 ์žฅ ๊ฒฐ๋ก  63 ์ฐธ๊ณ ๋ฌธํ—Œ 65 Abstract 69Maste
    • โ€ฆ
    corecore